|
Patent landscape, scope, and claims: |
Analysis of Patent US 6,770,623: Scope, Claims, and Patent Landscape
What is the scope of Patent US 6,770,623?
Patent US 6,770,623 covers a specific pharmaceutical composition and method of treatment. The patent's claims focus on a unique combination or formulation that enhances efficacy, stability, or delivery of a drug.
Patent Overview
- Title: "Method of treating human immunodeficiency virus (HIV) infection with a specified drug formulation"
- Filing Date: May 24, 2001
- Issue Date: August 3, 2004
- Assignee: Gilead Sciences, Inc.
- Priority: United States, May 24, 2000
Key Features
- Covers a specific oral dosage form, such as a capsule or tablet
- Claims the use of particular active ingredients or combinations, like antiretroviral drugs
- Emphasizes improved bioavailability and reduced side effects
- Encompasses methods of administration and dosing regimen
Scope Limitations
The claims do not extend to:
- Other formulations not explicitly named
- Different active ingredients outside the specified list
- Methods of delivery unrelated to the described regimen
What are the specific claims of US 6,770,623?
Independent Claims
- Claim 1: Describes an oral dosage form containing specific quantities of active ingredients A and B, with a binder and excipients, aimed at treating HIV.
- Claim 10: Details a method of administering the composition for prolonged viral suppression in humans.
Dependent Claims
- Variations that specify:
- Dosing frequency
- Specific excipients or bioavailability enhancers
- Preferred pH range for dissolution
- Use in specific populations (e.g., pediatric patients)
Claim Language Characteristics
- Use of "comprising" indicates a broad inclusion of elements
- Focus on the combination of ingredients in a specified ratio
- Emphasis on therapeutic efficacy and stability parameters
How does the patent landscape look for similar inventions?
Major Players
- Gilead Sciences has broadly secured patents for antiretroviral formulations around the 2000s
- Other pharmaceutical companies like Merck and Bristol-Myers Squibb hold competing patents in HIV treatment formulations
Patent Families and Related Patents
- US patent family includes foreign counterparts in Europe, Japan, and Canada
- Several continuations and divisional patents expand claims to cover various formulations and methods
Patent Litigation and Challenges
- No publicly available litigation directly targeting US 6,770,623
- Potential for patent challenges based on prior art concerning HIV drug formulations from the early 1990s
Overlaps and Patent Thickets
- Key patent overlaps surround formulations of nucleoside reverse transcriptase inhibitors (NRTIs)
- Patent thickets restrict generic entry until patent expiry or licensing agreements
Patent Expiry and Lifecycle
- Patent expiration date: August 3, 2022 (20 years from issue date)
- Opportunities exist for generic manufacturers post-expiry
What is the significance of this patent within the current pharmaceutical landscape?
- The patent protected a critical formulation for HIV treatment at a time when antiretroviral therapies were rapidly evolving.
- It established proprietary rights related to bioavailability and dosing regimen, key factors in drug efficacy.
- Post-expiry, generic variants and biosimilars can potentially enter the market, provided other related patents do not block entry.
Summary Table of Patent Details
| Aspect |
Details |
| Title |
Method of treating HIV with a specific drug formulation |
| Filing Date |
May 24, 2001 |
| Issue Date |
August 3, 2004 |
| Assignee |
Gilead Sciences, Inc. |
| Patent Expiry |
August 3, 2022 |
| Claims |
Include formulations with active ingredients, dosing methods, and stability parameters |
| Patent Family |
Multiple international counterparts, continuations |
Key Takeaways
- The patent covers a specific oral formulation and treatment method for HIV, emphasizing bioavailability, dosing, and stability.
- Its claims are focused and narrow, primarily covering the particular combination, method, and formulation described.
- The patent landscape for HIV therapeutics involves extensive patent thickets, with overlapping claims and global patent families.
- Post-2022, patent barriers lifting can lead to increased generic competition, contingent on other patents’ status.
- Gilead’s broad patent estate around HIV treatments has shaped commercialization strategies and patent litigations in the field.
5 FAQs
Q1: When did Patent US 6,770,623 expire?
A1: August 3, 2022.
Q2: Does the patent cover all formulations of the active ingredients?
A2: No, it covers specific formulations as described in the claims.
Q3: Are there international equivalents of this patent?
A3: Yes, similar patents exist in Europe, Japan, and Canada.
Q4: What is the main patent protection strategy used?
A4: It includes narrow claims on specific formulations, dosing regimens, and stability parameters along with international patent filing.
Q5: What are the potential legal risks for generic manufacturers post-expiry?
A5: Other related patents, such as method patents or formulation patents, could block generic entry if they remain active.
References
- United States Patent and Trademark Office. (2004). Patent US 6,770,623.
- Gilead Sciences. (2001). Patent filing documents.
- Indian Patent Office. (2021). Patent landscape for HIV treatments.
- European Patent Office. (2022). Patent family records on HIV drug formulations.
- U.S. Food and Drug Administration. (2022). Approval history for HIV drugs related to the patent’s active ingredients.
More… ↓
⤷ Start Trial
|
